Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILOR vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DILOR (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway responsiveness to stimuli. It also exhibits anti-inflammatory effects and enhances mucociliary clearance. Unlike theophylline, dyphylline is not converted to theophylline in vivo.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
FDA-approved: Relief of acute bronchial asthma and reversible bronchospasm associated with chronic bronchitis and emphysema.,Off-label: Treatment of apnea of prematurity (limited use).
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
DILOR (Dyphylline) 200-400 mg orally every 6 hours; maximum 1.6 g/day. Also available as IM injection: 250-500 mg every 6 hours.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Terminal elimination half-life is 3-4 hours in adults; may be prolonged in neonates, elderly, and patients with hepatic or cardiac dysfunction. Theophylline is a narrow therapeutic index drug; half-life dictates dosing frequency and need for therapeutic drug monitoring.
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Dyphylline is primarily metabolized by the liver via oxidation, with a smaller portion undergoing N-demethylation and oxidation. It is not metabolized to theophylline. Approximately 80% of the dose is excreted unchanged in the urine, indicating minimal hepatic metabolism.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Renal: approximately 50% unchanged drug; biliary/fecal: minimal (less than 10%). The remainder undergoes hepatic metabolism.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Approximately 40% bound to plasma proteins, primarily albumin.
65% bound to albumin
0.3-0.7 L/kg, approximating total body water; higher in neonates and patients with decreased protein binding (e.g., hepatic disease).
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Oral immediate-release: 100% (well absorbed); Extended-release formulations have comparable bioavailability with slower absorption.
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
Cr Cl 50-80 m L/min: 75% of dose; Cr Cl 25-50 m L/min: 50% of dose; Cr Cl <25 m L/min: 25% of dose; hemodialysis: administer after dialysis at 50% of dose.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
No specific Child-Pugh based adjustments established; use with caution in severe hepatic impairment due to potential reduced clearance.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
Not recommended for use in children; safety and efficacy not established. If used: 3-5 mg/kg orally every 6 hours, titrate to serum levels.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Start at lower end of dosing (200 mg every 6 hours) due to potential age-related decline in renal function; monitor serum levels and adjust based on Cr Cl.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
None
No FDA black box warning.
Use with caution in patients with peptic ulcer disease, hyperthyroidism, glaucoma, diabetes mellitus, severe hypoxemia, hypertension, arrhythmias, congestive heart failure, and renal impairment. Monitor serum levels; toxicity can occur at high doses. Concurrent use with other xanthines may increase toxicity. May cause seizures, arrhythmias, and death if serum levels exceed the therapeutic range.
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to dyphylline or any component of the formulation; history of seizure disorder (unless adequately controlled); active gastrointestinal hemorrhage; concurrent use of other xanthine derivatives (e.g., theophylline, caffeine).
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
Avoid large amounts of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase the risk of side effects like nervousness and palpitations. No other significant food interactions.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
DILOR (diprophylline) is a xanthine derivative. Animal studies have not shown teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Risk cannot be ruled out. Fetal risks are considered low, but caution is advised during all trimesters.
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Diprophylline is excreted into human milk. The M/P ratio is unknown. Potential adverse effects in infants include irritability and poor feeding. Weigh benefits against risks. Consider alternative bronchodilators if possible.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
No specific dose adjustments recommended due to pregnancy. Pharmacokinetic changes in pregnancy may decrease drug clearance; monitor clinical response and adjust dose if needed based on efficacy and toxicity.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
DILOR (diprophylline) is a xanthine bronchodilator less potent than theophylline but with fewer GI side effects; monitor for nausea, tremor, tachycardia; use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders; drug interactions include cimetidine, fluoroquinolones, and oral contraceptives which decrease clearance; theophylline levels are not routinely measured but toxicity can occur at high doses.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Take exactly as prescribed; do not double doses.,Report persistent nausea, vomiting, rapid heartbeat, or chest pain.,Avoid excessive caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Inform all healthcare providers you are taking this medication.,Do not stop abruptly without consulting your doctor.,Store at room temperature away from heat and moisture.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILOR vs AEROLATE, answered by our medical review team.
DILOR is a Bronchodilator that works by DILOR (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway responsiveness to stimuli. It also exhibits anti-inflammatory effects and enhances mucociliary clearance. Unlike theophylline, dyphylline is not converted to theophylline in vivo.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILOR and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILOR is: DILOR (Dyphylline) 200-400 mg orally every 6 hours; maximum 1.6 g/day. Also available as IM injection: 250-500 mg every 6 hours.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILOR and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILOR is classified as Category C. DILOR (diprophylline) is a xanthine derivative. Animal studies have not shown teratogenic effects. There are no adequate and well-controlled studies in pregnant women. Risk cannot . AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.